Evidence map›Paper›PMID 26474390›Full record

ArticleHepatology (Baltimore, Md.)2016

Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans.

Christabel Kelly, Leo Swadling, Stefania Capone, Anthony Brown, Rachel Richardson, John Halliday, Annette von Delft, Ye Oo, David Mutimer, Ayako Kurioka and 16 more

Open access · hybridAbstract read
In one paragraph

Article in Hepatology (Baltimore, Md.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Review
  4. Review
  5. Article
  6. New insights into T-cell exhaustion in liver cancer: from mechanism to therapy.Journal of cancer research and clinical oncology · 2023
    Review
  7. Article
  8. NK cells limit therapeutic vaccine-induced CD8Science translational medicine · 2022
    Article
  9. Review
  10. Review
  11. Article
  12. Lymphocyte Landscape after ChronicInternational journal of molecular sciences · 2020
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. HIV, HCV and HBV: A Review of Parallels and Differences.Infectious diseases and therapy · 2018
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 4 institutions in 2 countries.

Christabel KellyNuffield Department of Medicine, University of Oxford, Oxford, UK.
Leo SwadlingNuffield Department of Medicine, University of Oxford, Oxford, UK.
Stefania CaponeReiThera Srl (formerly Okairos Srl), Viale Città d'Europa, Rome, Italy.
Anthony BrownNuffield Department of Medicine, University of Oxford, Oxford, UK.
Rachel RichardsonNuffield Department of Medicine, University of Oxford, Oxford, UK.
John HallidayNuffield Department of Medicine, University of Oxford, Oxford, UK.
Annette von DelftNuffield Department of Medicine, University of Oxford, Oxford, UK.
Ye OoDepartment of Hepatology, Queen Elizabeth Hospital, Birmingham, UK.
David MutimerDepartment of Hepatology, Queen Elizabeth Hospital, Birmingham, UK.
Ayako KuriokaNuffield Department of Medicine, University of Oxford, Oxford, UK.
Felicity HartnellNuffield Department of Medicine, University of Oxford, Oxford, UK.
Jane CollierOxford NIHR BRC and Translational Gastroenterology Unit, Oxford, UK.
Virginia AmmendolaReiThera Srl (formerly Okairos Srl), Viale Città d'Europa, Rome, Italy.
Mariarosaria Del SorboReiThera Srl (formerly Okairos Srl), Viale Città d'Europa, Rome, Italy.
Fabiana GrazioliReiThera Srl (formerly Okairos Srl), Viale Città d'Europa, Rome, Italy.
Maria Luisa EspositoReiThera Srl (formerly Okairos Srl), Viale Città d'Europa, Rome, Italy.
Stefania Di MarcoReiThera Srl (formerly Okairos Srl), Viale Città d'Europa, Rome, Italy.
Loredana SianiReiThera Srl (formerly Okairos Srl), Viale Città d'Europa, Rome, Italy.
Cinzia TraboniReiThera Srl (formerly Okairos Srl), Viale Città d'Europa, Rome, Italy.
Adrian V S HillNuffield Department of Medicine, University of Oxford, Oxford, UK.
Stefano CollocaReiThera Srl (formerly Okairos Srl), Viale Città d'Europa, Rome, Italy.
Alfredo NicosiaOxford NIHR BRC and Translational Gastroenterology Unit, Oxford, UK.
Riccardo CorteseKeires AG, Basel, Switzerland.
Antonella FolgoriReiThera Srl (formerly Okairos Srl), Viale Città d'Europa, Rome, Italy.
Paul KlenermanNuffield Department of Medicine, University of Oxford, Oxford, UK.
Eleanor BarnesNuffield Department of Medicine, University of Oxford, Oxford, UK.
University of Oxford · GBJenner Institute · GBQueen Elizabeth Hospital Birmingham · GBCeinge Biotecnologie Avanzate (Italy) · IT

Funding

Virology CoreU19AI082630 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG, GEORG Michael LAUER · 2009 to 2026
$48.1M
Medical Research Council G0701694Medical Research Council G1002552Medical Research Council MR/K010239/1NIAID NIH HHS 2U19AI082630-06NIAID NIH HHS U19 AI082630Wellcome Trust 091663Wellcome Trust 109965/Z/15/Z
6 · The paper itself

Abstract

unlabelledAdenoviral vectors encoding hepatitis C virus (HCV) nonstructural (NS) proteins induce multispecific, high-magnitude, durable CD4(+) and CD8(+) T-cell responses in healthy volunteers. We assessed the capacity of these vaccines to induce functional HCV-specific immune responses and determine T-cell cross-reactivity to endogenous virus in patients with chronic HCV infection. HCV genotype 1-infected patients were vaccinated using heterologous adenoviral vectors (ChAd3-NSmut and Ad6-NSmut) encoding HCV NS proteins in a dose escalation, prime-boost regimen, with and without concomitant pegylated interferon-α/ribavirin therapy. Analysis of immune responses ex vivo used human leukocyte antigen class I pentamers, intracellular cytokine staining, and fine mapping in interferon-γ enzyme-linked immunospot assays. Cross-reactivity of T cells with population and endogenous viral variants was determined following viral sequence analysis. Compared to healthy volunteers, the magnitude of HCV-specific T-cell responses following vaccination was markedly reduced. CD8(+) HCV-specific T-cell responses were detected in 15/24 patients at the highest dose, whereas CD4(+) T-cell responses were rarely detectable. Analysis of the host circulating viral sequence showed that T-cell responses were rarely elicited when there was sequence homology between vaccine immunogen and endogenous virus. In contrast, T cells were induced in the context of genetic mismatch between vaccine immunogen and endogenous virus; however, these commonly failed to recognize circulating epitope variants and had a distinct partially functional phenotype. Vaccination was well tolerated but had no significant effect on HCV viral load.

conclusionVaccination with potent HCV adenoviral vectored vaccines fails to restore T-cell immunity except where there is genetic mismatch between vaccine immunogen and endogenous virus; this highlights the major challenge of overcoming T-cell exhaustion in the context of persistent antigen exposure with implications for cancer and other persistent infections.

Indexed as

AdenoviridaeAdultAgedAmino Acid SequenceEpitopes, T-LymphocyteHepacivirusHepatitis C, ChronicHumansInterferon-alphaMaleMiddle AgedMolecular Sequence DataPolyethylene GlycolsRecombinant ProteinsRiboflavinT-LymphocytesEpitopes, T-LymphocyteInterferon-alphapeginterferon alfa-2aPolyethylene GlycolsRecombinant ProteinsRiboflavinViral Hepatitis Vaccines

Identifiers

PMID26474390
PMCPMC4842008
OpenAlexW2126697685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.